12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EMA401: Phase II data

A double-blind, international Phase II trial in 183 patients with PHN showed that twice-daily 100 mg oral EMA401 met the primary endpoint of reducing mean daily pain intensity score from baseline to week 4 vs. placebo (2.34 vs. 1.64 points, p=0.006). EMA401 also met the secondary endpoint of a greater...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >